Travere holder FMR reports 11.7% ownership

Travere Therapeutics Inc. received a Schedule 13G filing showing that FMR LLC and Abigail P. Johnson beneficially own 10,567,302.78 shares of its common stock, representing 11.7% of the class as of 12/31/2025.

Accepted by SEC EDGAR 01/08/2026 - 09:09 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Travere Therapeutics Inc. received a Schedule 13G filing showing that FMR LLC and Abigail P. Johnson beneficially own 10,567,302.78 shares of its common stock, representing 11.7% of the class as of 12/31/2025. FMR LLC reports sole voting power over 10,224,163.76 shares and sole dispositive power over 10,567,302.78 shares, while Abigail P. Johnson reports sole dispositive power over the same 10,567,302.78 shares.

The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Travere Therapeutics. It also notes that one or more other persons may have the right to receive dividends or proceeds from these shares, but no single such person holds more than five percent of the outstanding common stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Travere Therapeutics (TVTX) shares does FMR LLC beneficially own?

FMR LLC reports beneficial ownership of 10,567,302.78 shares of Travere Therapeutics common stock, as disclosed in the Schedule 13G.

What percentage of Travere Therapeutics (TVTX) does FMR LLC and Abigail P. Johnson own?

The filing reports beneficial ownership of 11.7% of Travere Therapeutics' common stock by the reporting persons.

Does FMR LLC intend to influence control of Travere Therapeutics (TVTX)?

The certification states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Travere Therapeutics.

What voting and dispositive powers does FMR LLC report over Travere Therapeutics (TVTX) shares?

FMR LLC reports sole voting power over 10,224,163.76 shares and sole dispositive power over 10,567,302.78 shares, with no shared voting or dispositive power.

What role does Abigail P. Johnson have in the Travere Therapeutics (TVTX) Schedule 13G?

Abigail P. Johnson is a reporting person on the Schedule 13G, reporting sole dispositive power over 10,567,302.78 shares and no voting power, with her type of reporting person listed as IN (individual).

Are there other parties with economic interests in the Travere Therapeutics (TVTX) shares reported by FMR LLC?

The filing notes that one or more other persons may have the right to receive dividends or sale proceeds from the Travere Therapeutics common stock, but no such person has more than 5% of the total outstanding common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

TRAVERE THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

89422G107

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 89422G107

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 10,224,163.76
6	Shared Voting Power 0.00
7	Sole Dispositive Power 10,567,302.78
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

10,567,302.78

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

11.7 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 89422G107

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 10,567,302.78
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

10,567,302.78

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

11.7 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: TRAVERE THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 3611 VALLEY CENTRE DR,SUITE 300,SAN DIEGO,CA,US,92130
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 89422G107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 10567302.78
(b)	Percent of class: 11.7 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 10567302.78
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of TRAVERE THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of TRAVERE THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Stephanie J. Brown
Name/Title:	Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	01/07/2026

Abigail P. Johnson

Signature:	Stephanie J. Brown
Name/Title:	Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
Date:	01/07/2026

Comments accompanying signature: * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.